Related Experiment Video
Updated: Jan 14, 2026
06:24
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
Published on: January 10, 2025
1.4K
Dynamic changes in IGF-1 levels during cabergoline therapy in prolactinoma
Ahmet Numan Demir1, Alara Birol2, Dilan Ozaydin3
1Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Summary
Cabergoline treatment for prolactinoma may initially increase then decrease insulin-like growth factor-1 (IGF-1) levels. Longer treatment and higher doses correlate with IGF-1 reduction, though clinical significance requires further study.
Area of Science:
- Endocrinology
- Pharmacology
- Oncology
Background:
- Cabergoline is a dopamine agonist used for prolactinoma.
- Its long-term effects on insulin-like growth factor-1 (IGF-1) in prolactinoma patients are not well understood.
- Cabergoline is known to suppress growth hormone (GH) and IGF-1.
Purpose of the Study:
- To assess changes in IGF-1 levels in prolactinoma patients receiving cabergoline.
- To identify factors influencing these IGF-1 level changes.
- To evaluate the relationship between cabergoline dosage, treatment duration, and IGF-1 levels.
Main Methods:
- Retrospective cohort study of 127 prolactinoma patients treated with cabergoline (2013-2023).
- Exclusion of patients with conditions affecting IGF-1.
- Comparison of IGF-1 and IGF-1xULN levels at baseline and last follow-up.
- Regression and ROC analyses to assess associations with treatment duration, cumulative dose, and tumor features.
Main Results:
- Median follow-up was 36 months.
- Final IGF-1 and IGF-1xULN levels were significantly lower than baseline (p < 0.05).
- Decreased IGF-1xULN was linked to longer treatment duration and higher cumulative cabergoline doses (p < 0.05).
- Predictors for IGF-1 reduction included cumulative dose ≥60 mg and treatment duration ≥18 months.
Conclusions:
- Cabergoline therapy for prolactinoma may cause an initial rise followed by a decline in IGF-1 levels.
- Reductions in IGF-1, even within normal limits, require further investigation.
- Prospective studies with defined metabolic endpoints are needed to clarify the clinical significance.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
677
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
677
01:22Target Cell Response to Hormones
5.1K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.1K